Lee, H., Flinn, I. W., Melear, J., Ramchandren, R., Friedman, J., Burke, J. M., Linhares, Y., Raval, M., Chintapatla, R., Feldman, T. A., Yimer, H., Islas-Ohlmayer, M., Dean, A., Rana, V., Gandhi, M. D., Renshaw, J., Gillespie-Twardy, A. L., Ho, L., Puhlmann, M., Guo, W., & Yasenchak, C. A. (n.d.). p1089: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE (AN+AD) FOR ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY (SGN35 027 PART B). HemaSphere, 6, 979–980. http://access.bl.uk/ark:/81055/vdc_100159756595.0x000006